Antiproliferative effects of N-heterocyclic indolyl glyoxylamide derivatives on human lung cancer cells

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3407-3415

  Huang, Tien Heng ^a   Chiu, Shu Jun ^b,c   Chiang, Pei Hsiuang ^a   Chiou, Shih Hwa ^a,d   Li, Wen Tai ^e   Chen, Chiung Tong ^e   Chang, C Allen ^a   Chen, Jyh Cheng ^a   Lee, Yi Jang ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

G 2 m phase arrest; Human lung cancer cells; N heterocyclic indolyl glyoxylamides; p53 independent apoptosis; Radiosensitivity

Indexed keywords

ANTINEOPLASTIC AGENT; BPR 0C 123; BPR 0C 259; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; HETEROCYCLIC COMPOUND; N1 (3 METHYL 5 ISOTHIAZOLYL) 2 [1 (2 FURYLMETHYL) 1H 3 INDOLYL] 2 OXOACETAMIDE; N1 (3 METHYL 5 ISOTHIAZOLYL) 2 [1 (4 CYANOBENZYL) 1H 3 INDOLYL] 2 OXOACETAMIDE; PROTEIN P53; SERINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SCREENING; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; UPREGULATION;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; RADIATION, IONIZING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80054722088     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Li WT, Hwang DR, Chen CP, Shen CW, Huang CL, Chen TW, Lin CH, Chang YL, Chang YY, Lo YK, Tseng HY, Lin CC, Song JS, Chen HC, Chen SJ, Wu SH and Chen CT: Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. J Med Chem 46(9): 1706-1715, 2003. (Pubitemid 36444223)
2. Schmidt M, Lu Y, Parant JM, Lozano G, Bacher G, Beckers T and Fan Z: Differential roles of p21(Waf1) and p27(Kip1) in modulating chemosensitivity and their possible application in drag discovery studies. Mol Pharmacol 60(5): 900-906, 2001. (Pubitemid 33027424)
3. Bacher G, Nickel B, Emig P, Vanhoefer U, Seeber S, Shandra A, Klenner T and Beckers T: D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res 61(1): 392-399, 2001. (Pubitemid 32106651)
4. Hu CB, Chen CP, Yeh TK, Song JS, Chang CY, Chuu JJ, Tung FF, Ho PY, Chen TW, Lin CH, Wang MH, Chang KY, Huang CL, Lin HL, Li WT, Hwang DR, Chern JH, Hwang LL, Chang JY, Chao YS and Chen CT: BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities. Cancer Sci 102(1): 182-191, 2011.
5. Ko LJ and Prives C: p53: puzzle and paradigm. Genes Dev 10(9): 1054-1072, 1996. (Pubitemid 26152848)
6. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88(3): 323-331, 1997.
7. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408(6810): 307-310, 2000.
8. Dumaz N and Meek DW: Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J 18(24): 7002-7010, 1999. (Pubitemid 30000453)
9. Nakagawa K, Taya Y, Tamai K and Yamaizumi M: Requirement of ATM in phosphorylation of the human p53 protein at serine 15 following DNA double-strand breaks. Mol Cell Biol 19(4):2828-2834, 1999. (Pubitemid 29144526)
10. Bohnke A, Westphal F, Schmidt A, El-Awady RA and Dahm-Daphi J: Role of p53 mutations, protein function and DNA damage for the radiosensitivity of human tumour cells. Int J Radiat Biol 80(1): 53-63, 2004. (Pubitemid 38365712)
11. Goh AM, Coffill CR and Lane DP: The role of mutant p53 in human cancer. J Pathol 223(2): 116-126, 2011.
12. Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP and Khanna KK: Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene 29(46): 6085-6098, 2010.
13. Amaral JD, Xavier JM, Steer CJ and Rodrigues CM: Targeting the p53 pathway of apoptosis. Curr Pharm Des 16(22): 2493-2503, 2010.
14. .Ito H, Kanzawa T, Kondo S and Kondo Y: Microtubule inhibitor D-24851 induces p53-independent apoptotic cell death in malignant glioma cells through BCL-2 phosphorylation and BAX translocation. Int J Oncol 26(3): 589-596, 2005.
15. Pawlik TM and Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59(4): 928-942, 2004. (Pubitemid 38834285)
16. Zanelli GD, Quaia M, Robieux I, Bujor L, Santarosa M, Favaro D, Spada A, Caffau C, Gobitti C and Trovo MG: Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations. Eur J Cancer 33(3): 486-492, 1997. (Pubitemid 27168078)
17. Choy H: Taxanes in combined modality therapy for solid tumors. Crit Rev Oncol Hematol 37(3): 237-247, 2001.
18. WAF/CIP1l following destabilization of the actin cytoskeleton. Int J Oncol 34(2): 581-589, 2009.
19. Hursting SD and Berger NA: Energy balance, host-related factors, and cancer progression. J Clin Oncol 28(26): 4058-4065, 2010.
20. Lutgendorf SK, Sood AK and Antoni MH: Host factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncol 28(26): 4094-4099, 2010.
21. Ishikawa T and Nakagawa H: Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. J Exp Ther Oncol 8(1): 5-24, 2009.
22. Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22, 2007.
23. Hemann MT, Zilfou JT, Zhao Z, Burgess DJ, Hannon GJ and Lowe SW: Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci USA 101(25): 9333-9338, 2004. (Pubitemid 38812876)
24. Matsui Y, Tsuchida Y and Keng PC: Effects of p53 mutations on cellular sensitivity to ionizing radiation. Am J Clin Oncol 24(5): 486-490, 2001. (Pubitemid 32959107)
25. Wu L and Levine AJ: Differential regulation of the p21/WAF-1 and MDM2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the MDM2 gene. Mol Med 3(7): 441-451, 1997. (Pubitemid 27438768)
26. Maebayashi K, Mitsuhashi N, Takahashi T, Sakurai H and Niibe H: p53 mutation decreased radiosensitivity in rat yolk sac tumor cell lines. Int J Radiat Oncol Biol Phys 44(3): 677-682, 1999. (Pubitemid 29258444)
27. Sedletska Y, Giraud-Panis MJ and Malinge JM: Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 5(3): 251-265, 2005. (Pubitemid 40655276)